`Sent:
`To:
`Cc:
`
`Subject:
`
`Nick,
`
`Uma Everett <UEVERETT@sternekessler.com>
`Wednesday, January 16, 2019 3:12 PM
`Daniel Wiesner; JC Rozendaal; Michael Joffre; Will Milliken
`Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-
`Antwi (EOfosuantwi@walsh.law); clizza@saul.com; Moses, David L.
`<dmoses@saul.com>; Sarah Sullivan; Slavin, Elina; WBaton@saul.com
`RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632
`(D.N.J.)
`
`We have further considered your scheduling proposal in exchange for bifurcating Teva's patent misuse defense. As you
`know, Teva's ANDA product has received tentative approval, and the only thing preventing Teva's launch at the end of
`February 2019 is the 30-month stay based on Corcept's meritless lawsuit. Therefore, Teva cannot agree to a schedule
`that extends resolution of the asserted patents beyond the 30-month stay (i.e., August 2020). In addition, Teva does not
`consent to the addition of any additional patent to this litigation, particularly if the addition would result in delay of the
`trial. It thus appears that the parties cannot reach resolution and will need to submit competing schedules to the Court
`in advance of our February 11th Rule 16 conference. Under the circumstances, we cannot agree to bifurcate Teva’s
`patent misuse defense.
`
`Regards,
`Uma
`
`Uma Everett
`Director
`Sterne, Kessler, Goldstein & Fox P.L.L.C.
`Email: ueverett@sternekessler.com
`Direct: 202.772.8520
`
`Administrative Assistant: Chelsea Santiago
`Direct: 202.772.8894 Main: 202.371.2600
`
`From: Daniel Wiesner [mailto:danielwiesner@quinnemanuel.com]
`Sent: Monday, January 14, 2019 12:51 PM
`To: Uma Everett; JC Rozendaal; Michael Joffre; Will Milliken
`Cc: Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-Antwi
`(EOfosuantwi@walsh.law); clizza@saul.com; Moses, David L. <dmoses@saul.com>; Sarah Sullivan; Slavin, Elina;
`WBaton@saul.com
`Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)
`
`Yes, that works. We can use the below dial-in:
`
`Tel: 866-499-9580
`Code: 9080950
`
`Thanks,
`Dan
`
`1
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2003, Page 1
`
`
`
`From: Uma Everett [mailto:UEVERETT@sternekessler.com]
`Sent: Monday, January 14, 2019 10:56 AM
`To: Daniel Wiesner <danielwiesner@quinnemanuel.com>; JC Rozendaal <JCROZENDAAL@sternekessler.com>; Michael
`Joffre <MJOFFRE@sternekessler.com>; Will Milliken <WMilliken@sternekessler.com>
`Cc: Nick Cerrito <nickcerrito@quinnemanuel.com>; Eric Stops <ericstops@quinnemanuel.com>; John Galanek
`<johngalanek@quinnemanuel.com>; Liza Walsh (LWalsh@walsh.law) <LWalsh@walsh.law>; Eleonore Ofosu-Antwi
`(EOfosuantwi@walsh.law) <EOfosuantwi@walsh.law>; clizza@saul.com; Moses, David L. <dmoses@saul.com>
`<dmoses@saul.com>; Sarah Sullivan <Sarah.Sullivan@saul.com>; Slavin, Elina <Elina.Slavin@saul.com>;
`WBaton@saul.com
`Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)
`
`Dan,
`
`We are available to speak on Tuesday at 4:30 p.m. Does that work for your team?
`
`Regards,
`Uma
`
`From: Daniel Wiesner [mailto:danielwiesner@quinnemanuel.com]
`Sent: Friday, January 11, 2019 5:00 PM
`To: Uma Everett; JC Rozendaal; Michael Joffre; Will Milliken
`Cc: Nick Cerrito; Eric Stops; John Galanek; Liza Walsh (LWalsh@walsh.law); Eleonore Ofosu-Antwi
`(EOfosuantwi@walsh.law); clizza@saul.com; Moses, David L. <dmoses@saul.com>; Sarah Sullivan; Slavin, Elina;
`WBaton@saul.com
`Subject: RE: Corcept Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. et al., No. 18-3632 (D.N.J.)
`
`Uma,
`
`Thank you for your email. Corcept’s scheduling proposal is attached. As your team suggested during the call last week,
`Corcept’s proposed schedule accounts for adding to the case relevant patents that have either recently issued or
`recently been granted a notice of allowance.
`
`It would probably make sense to arrange another call for next week to discuss the schedule. We are generally available
`Tuesday afternoon; please let us know if there is a time that works for your team.
`
`Regards,
`Dan
`
`Daniel Wiesner
`Of Counsel
`Quinn Emanuel Urquhart & Sullivan, LLP
`
`51 Madison Avenue, 22nd Floor
`New York, NY 10010
`212-849-7560 Direct
`212-849-7000 Main Office Number
`212-849-7100 FAX
`danielwiesner@quinnemanuel.com
`www.quinnemanuel.com
`
`2
`
`Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc.
`PGR2019-00048
`Corcept Ex. 2003, Page 2
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
